Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Ledermann

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Gynecologic Oncology|April 22, 2019
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumorMartin Gore, Allan Hackshaw, William E Brady, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovaryAikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, et al.
Genome Medicine|December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparibAlan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapyAngelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Gynecologic Oncology|April 22, 2019
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumorMartin Gore, Allan Hackshaw, William E Brady, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovaryAikou Okamoto, Rosalind M Glasspool, Seiji Mabuchi, et al.
Genome Medicine|December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparibAlan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapyAngelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Pageof 5